Fast dissolving β-lapachone particles and tablets: An approach using surface adsorption technique

Drug Development and Industrial Pharmacy

Volumn 38, Issue 7, 2012, Pages 866-871

  Cunha Filho, Marcílio S S ^a   Martínez Pacheco, Ramón ^b   Landin, Mariana ^b  

^a FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Dissolution rate; Microcrystalline cellulose; Surface adsorption technique; Tablets; Lapachone

Indexed keywords

BETA LAPACHONE; MICROCRYSTALLINE CELLULOSE; ANTIINFECTIVE AGENT; BETA-LAPACHONE; CELLULOSE; EXCIPIENT; NAPHTHOQUINONE; POWDER; TABLET;

ARTICLE; CHEMICAL ANALYSIS; DRUG ABSORPTION; DRUG DETERMINATION; DRUG SOLUBILITY; HUMAN; PHYSICAL CHEMISTRY; TABLET; ADSORPTION; CHEMISTRY; CRYSTALLIZATION; MEDICINAL CHEMISTRY; PARTICLE SIZE; POWDER; PROCEDURES; SOLUBILITY;

ADSORPTION; ANTI-INFECTIVE AGENTS; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; EXCIPIENTS; NAPHTHOQUINONES; PARTICLE SIZE; POWDERS; SOLUBILITY; TABLETS;

EID: 84861488531     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.630396     Document Type: Article

References (21)

1. Gonçalves de Lima O, D'Albuquerque IL, Machado MP, Silva E, Pinto GP. (1956). Primeiras observações sobre a ação antimicrobiana do lapachol. An Soc Biol Pe, 14:129-135.
2. Gómez Castellanos JR, Prieto JM, Heinrich M. (2009). Red Lapacho (Tabebuia impetiginosa)-a global ethnopharmacological commodity? J Ethnopharmacol, 121:1-13.
3. De Moura KCG, Emery FS, Neves-Pinto C, Pinto MCFR, Dantas AP., Salomão K, De Castro SL, Pinto AV. (2001). Trypanocidal activity of isolated naphthoquinones from Tabebuia and some heterocyclic derivatives: A review from an interdisciplinary study. Braz Chem Soc, 12:325-338.
4. U.S. National Institute of Health. (2011). ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/results?term=ARQ+501. Accessed on 23 August 2011.
5. Boveris A, Docampo R, Turrens J F, Stoppani AO. (1978). Efect of β-lapachone on superoxide anion and hydrogen peroxide production in Trypanosoma cruzi. Biochem J, 175:431-439.
6. Docampo R, Lopes JN, Cruz FS, Souza W. (1977). Trypanosoma cruzi: Ultrastructural and metabolic alterations of epimastigotes by β-lapachone. Exp Parasitol, 42:142-149.
7. Pinto AV, de Castro SL. (2009). The trypanocidal activity of naphthoquinones: A review. Molecules, 14:4570-4590.
8. Cunha-Filho MS, Martínez-Pacheco R, Landín M. (2008). Dissolution rate enhancement of the novel antitumoral β-lapachone by solvent change precipitation of microparticles. Eur J Pharm Biopharm, 69:871-877.
9. Malpani A. (2009). Promising novel approaches for oral delivery of poorly soluble drugs. Pharm Rev, 7. Available at http://www. pharmainfo.net/reviews/ promising-novel-approaches-oral-delivery-poorly-soluble-drugs. Accessed on October 20 2011.
10. Alsaidan SM, Alsughayer AA, Eshra AG. (1998). Improved dissolution rate of indomethacin by adsorbents. Drug Dev Ind Pharm, 24:389-394.
11. Javadzadeh Y, Jafari-Navimipour B, Nokhodchi A. (2007). Liquid-solid technique for dissolution rate enhancement of a high dose water-insoluble drug (carbamazepine). Int J Pharm, 341: 26-34.
12. Johansen H, Moller N. (1978). Solvent deposition method for enhancement of dissolution rate: Importance of drug-to-excipient ratio. J Pharm Sci, 67:134-136.
13. Dastmalchi S, Garjani A, Maleki N, Sheikhee G, Baghchevan V, Jafari-Azad P et al. (2005). Enhancing dissolution, serum concentrations and hypoglycemic efect of glibenclamide using solvent deposition technique. J Pharm Pharm Sci, 8:175-181.
14. Cunha-Filho MS, Estévez-Braun A, Pérez-Sacau E, Echezarreta-López MM, Martínez-Pacheco R, Landín M. (2011). Light efect on the stability of β-lapachone in solution: Pathways and kinetics of degradation. J Pharm Pharmacol, 63:1156-1160.
15. Fell JT, Newton JM. (1970). The prediction of the tensile strength of tablets. J Pharm Pharmacol, 22:247-248.
16. U.S. Department of Health and Human Services. (1997). Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070237.pdf. Accessed on 10 May 2011.
17. Cunha-Filho MS, Dacunha-Marinho B, Torres-Labandeira JJ, Martínez-Pacheco R, Landín M. (2007). Characterization of β-lapachone and methylated β-cyclodextrin solid-state systems. AAPS PharmSciTech, 8:E60.
18. Khan KA, Rhodes CT. (1972). Efect of compaction pressure on the dissolution efciency of some direct compression systems. Pharm Acta Helv, 47:594-607.
19. Cunha-Filho MS, Landin M, Martinez-Pacheco R, Dacunha-Marinho B. (2006). β-lapachone. Acta Crystallogr C, 62:o473-o475.
20. Li CJ, Li YZ, Pinto AV, Pardee AB. (1999). Potent inhibition of tumor survival in vivo by β-lapachone plus taxol: Combining drugs imposes diferent artifcial checkpoints. Proc Natl Acad Sci USA, 96:13369-13374.
21. Shapiro G, Supko JG, Ryan DP, Appelman L, Berkenblit A, Craig AR, et al. (2005). Eder Phase I trial of ARQ 501, an Activated Checkpoint Terapy (ACT) agent, in patients with advanced solid tumors. Proceedings of 2005 ASCO Annual Meeting, Orlando, USA, 3042.